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Vector-infected dendritic cells (DC) are evaluated for antigen delivery in experimental therapy of cancer and infectious diseases. Here,
we investigated infections of immature or mature, monocyte-derived human DC with recombinant vaccinia virus MVA producing human
Her-2/neu, a candidate tumor-associated antigen. Assessment of the molecular virus life cycle in infected DC revealed a general arrest at the
level of viral early gene expression. When monitoring the phenotype of MVA-infected DC, including expression of cell surface markers, we
found immature cells readily undergoing apoptosis. Nevertheless, we detected significant populations of viable DC being characterized by
high level Her-2/neu expression and unimpaired display of costimulatory molecules. While infected viable immature DC failed to undergo
maturation despite cytokine treatment, both DC populations efficiently presented MVA-produced target antigen. These findings allow to
better define the requirements for MVA-mediated antigen delivery to DC and help to derive optimized vectors for this advanced therapy
option.
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Several poxviral vector systems are under clinical
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doi:10.1016/j.virol.2006.02.039cultures and became growth-restricted in many mammalian
cells including those of human origin (Carroll et al., 1997;
Drexler et al., 1998; Meyer et al., 1991). Importantly, upon
infection of non-permissive human cell lines (Ludwig et al.,
2005; Sutter and Moss, 1992), MVA can still initiate the full
cascade of vaccinia viral gene expression allowing for
recombinant genes to be placed under transcriptional control
of vaccinia virus-specific late promoters and for abundant
synthesis of heterologous antigens. Indeed, recombinant
MVA vaccines have been shown to stimulate immune
responses against a large variety of different antigens with
protective efficacy against viral infections, bacterial as well
as parasitic diseases and tumors (Carroll et al., 1997;
Drexler et al., 2004; McConkey et al., 2003; Sutter et al.,
Fig. 1. Construction of recombinant virus MVA-Her-2/neu and expression of
Her-2/neu target protein. (A) A schematic map of the MVA genome for the
restriction endonuclease HindIII is shown on top. The coding gene sequence of
her-2/neu was placed under the transcriptional control of VVearly/late promoter
P7.5 and inserted by homologous recombination at the site of deletion III within
the MVA genome. Flank 1 and flank 2 refer to MVA-DNA sequences that are
adjacent to the site of deletion III and serve to target the recombination into the
MVA genome. Del indicates the positions of 283-bp repetitive MVA-DNA
sequences corresponding to the right end of flank 1 and allowing the removal of
the K1L selectable marker from the genome of final recombinant viruses by
homologous recombination. (A) Representation of the genomic structure of
recombinant MVA-Her-2/neu is shown at the bottom. (B) Western blot analysis
of HeLa cell lysates prepared at 12 h post-infection with MVA or MVA-Her-2/
neu. The numbers to the left refer to the molecular weights of marker proteins (in
kilodalton) used during electrophoresis. (C) FACS analysis of Her-2/neu cell
surface expression in human LCL and a Her-2/neu-positive human tumor cell
line (SK-MEL-28) after MVA-Her-2/neu infection.
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already been tested in phase I or phase I/II clinical trials
(Cebere et al., 2006; Corona Gutierrez et al., 2004; Cosma
et al., 2003; Di Nicola et al., 2003; Di Nicola et al., 2004;
Harrer et al., 2005; Liu et al., 2004; McConkey et al., 2003;
McShane et al., 2004; Moorthy et al., 2004; Moorthy et al.,
2003; Mwau et al., 2004; Rochlitz et al., 2003; Smith et al.,
2005). One interesting approach is based on the combined
use of dendritic cells (DC) and recombinant MVA for
delivery of vaccine antigens. The idea behind joint
application of viral vector vaccines and professional
antigen-presenting cells is to induce more potent target
antigen-specific immune responses in the context of DC-
mediated immune signaling. This strategy could be advan-
tageous to enhance the immunogenicity of tumor-associated
antigens (TAA) being affected by immunological tolerance.
In a recent clinical phase I trial protocol, autologous CD34+
cell-derived DC were ex vivo infected with an MVA vector
virus expressing the human melanoma-associated antigen
tyrosinase and transferred to melanoma patients (Di Nicola
et al., 2003; Drexler et al., 1999). This therapeutic approach
resulted in a significant activation of tyrosinase-specific
CD8+T cells, suggesting efficient antigen presentation upon
MVA infection of DC (Di Nicola et al., 2004). In contrast,
more conventional vaccination of melanoma patients with
the same MVA vector virus failed to induce detectable T-
cell responses directed against the human self antigen
tyrosinase (Meyer et al., 2005). To better understand the
potential advantage of TAA delivery by MVA-infected DC,
we analyzed the effect of MVA infection in human
immature (iDC) or mature (mDC) antigen-presenting cells.
To assess transcriptional, translational and post-translational
levels of target gene expression, we used recombinant MVA
delivering human Her-2/neu, a 185-kDa cell surface protein,
to be easily monitored by antibody surface staining and
FACS analysis. Her-2/neu is also a potentially useful target
antigen for tumor immunotherapy because it was found to
be overexpressed in human malignant cells and to induce
specific cellular and humoral responses in breast cancer
patients (Disis et al., 1994; Disis et al., 1997; Park et al.,
2005). Upon infection of human DC, we found persisting
MVA early gene expression to result in substantial
production of Her-2/neu antigen. However, based on the
expression of relevant cell surface markers, infected iDC
were unable to undergo maturation even in the presence of
maturation inducing cytokines. In contrast, we found fully
preserved cell surface expression of costimulatory markers
on infected, but importantly, non-apoptotic mDC. Both
infected iDC and mDC were able to translate, process and
present recombinant antigen in an MHC-restricted manner
providing a rational basis to explain the in vivo
immunogenecity of DC-delivered MVA vaccines. Finally,
our work with MVA suggested a surprising difference to
previous infection experiments with standard replication
competent vaccinia virus resulting in downregulation of
costimulatory markers as well as MHC class I and class II
molecules on human DC.Results
Her-2/neu is produced by recombinant MVA and transported to
the cell surface
The recombinant virus MVA-Her-2/neu allowing expression
of the human her-2/neu gene sequence under transcriptional
control of the VV early/late promoter P7.5 was generated by
using the host range gene K1L as a transient selectable marker
(Fig. 1A). To confirm the synthesis of recombinant Her-2/neu
protein upon infection, we analyzed total cell extracts from
Fig. 2. Polypeptide synthesis in HeLa cells and DC infected with MVA or MVA-
Her-2/neu. HeLa cells and DC were infected at MOI 20 in the absence (A) or
presence (B) of AraC, polypeptides were metabolically labeled with [S35]
methionine and cell extracts were prepared at indicated times post-infection
(h p.i.). Proteins were separated by SDS-PAGE and analyzed by autoradio-
graphy. U refers to lanes with extracts from uninfected cells. (A) MVA
produces typical late viral proteins (indicated by black arrowheads) in HeLa
cells, but not in DC. (B) In the presence of AraC, no late viral proteins are
produced (white arrowheads indicate typical early proteins). (C) Viral early
proteins are made in mature and immature DC infected with MVA or MVA-
Her-2/neu, respectively. An arrow indicates the expected molecular weight of
recombinant Her-2/neu protein.
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proteins harvested at 12 h after infection, the anti-Her-2/neu
antibody Ab-2 revealed a single protein band migrating at the
molecular weight of 185 kDa and precisely corresponding to the
expected size of human Her-2/neu. Since Her-2/neu is a
transmembrane protein usually located on the cell surface, we
expected it to be detectable on MVA-Her-2/neu-infected cells
by FACS analysis using antibody staining. Indeed, as shown in
Fig. 1C, after infection of human LCL with MVA-Her-2/neu,
we found more than 50% of the cell population carrying the
target molecule while cells infected with non-recombinant
MVA as control remained negative upon staining. Additionally,
infection of human melanoma cells SK-Mel-28 which naturally
produce Her-2/neu resulted in obvious enhancement of Her-2/
neu cell surface expression (Fig. 1C). Therefore, MVA infection
by itself seemed not to impair the surface presentation of
endogenous Her-2/neu, allowing for efficient production and
transport of additional target protein.
MVA infection of human DC is restricted to the production of
viral early proteins
While recent data (Di Nicola et al., 2004) suggest that MVA-
infected human DC can be successfully used for recombinant
antigen delivery, there is still limited information on the MVA
molecular life cycle in these antigen-presenting cells. Moreover,
immune evasion rather than immune stimulation could be
expected from the results obtained with conventional VV
infection in human DC (Engelmayer et al., 1999). To monitor
for viral proteins being produced in infected DC, we performed
an [S35]methionine metabolic labeling of polypeptides in iDC
and mDC at various times after infection with MVA (Figs. 2A,
B) or MVA-Her-2/neu (Fig. 2C). To allow for comparison with
a well-characterized pattern of viral protein synthesis, infections
of human HeLa cells served as positive control (Figs. 2A, B).
Compared to the labeling of cellular proteins in mock-infected
cells (U), MVA infection resulted in the typical shut-off of host
cell protein synthesis in both DC and HeLa cells (Fig. 2A). At 2
h of infection, the pulse labeling revealed the characteristic
pattern of early viral polypeptides being made in iDC and mDC
which also resembled the pattern found for typical early viral
proteins made in HeLa cells (marked by white arrow heads in
Fig. 2A). At later time points of infection, the onset of abundant
late viral protein synthesis became very obvious in MVA-
infected HeLa cells illustrated by multiple new polypeptides of
varying molecular weight (typical late viral proteins are
indicated by black arrow heads in Fig. 2A). In contrast, we
failed to detect these late viral proteins in MVA-infected DC,
suggesting a failure of viral late gene expression in these
professional antigen-presenting cells. This notion was corrob-
orated by our finding of close to identical viral protein patterns
in MVA-infected DC in the presence of cytosine arabinoside
(AraC) serving as potent inhibitor of vaccinia virus DNA
replication and, in consequence, as inhibitor of viral interme-
diate and late gene expression (Fig. 2B). In addition, the
synthesis of recombinant Her-2/neu in MVA-Her-2/neu-
infected DC also suggested a restriction to viral early geneexpression (Fig. 2C). Already at 2 h post-infection, we detected
a protein being exclusively made in MVA-Her-2/neu, but not in
MVA-infected DC, signifying it as the recombinant Her-2/neu
(marked by an arrow in Fig. 2C). The labeling of this
polypeptide was clearly most intense at early times of infection
without indication of increased production late in infection
despite the recombinant gene being transcriptionally controlled
by the robust vaccinia virus early/late promoter P7.5. Thus, we
speculated that upon infection of both DC populations the MVA
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early gene expression being possibly maintained through later
times of infection.
Efficient Her-2/neu surface expression in DC after infection
with MVA-Her-2/neu
Unlike DC, the human cell lines SK-Mel-28 and LCL allow
for viral late gene expression (unpublished observations), and
we had confirmed high level synthesis of recombinant Her-2/
neu in these cells upon MVA vector infection (Fig. 1). In order
to obtain more detailed information on the efficacy of MVA-
driven target antigen production in DC, we performed a series
of infection experiments applying various doses of vector virus
MVA-Her-2/neu (ranging from MOI 1 to 100) to iDC or mDC.
Subsequently, Her-2/neu surface expression was monitored by
FACS (Fig. 3). At 12 h after infection, the percentage of Her-2/
neu-positive iDC increased from about 50% using MOI 1 up to
>90% using MOI 10. After infection of mDC, the number of
Her-2/neu-positive cells continuously augmented from about
20% at MOI 1 up to 99% at the highest MOI. To obtain similar
levels of Her-2/neu surface expression, MVA infection of mDC
appeared to require about two-fold more virus particles as
compared to infection of iDC. On the other hand, as judged by
the uniformity of the Her-2/neu surface expression, it looked as
if iDC were more fragile than mDC when exposed to unusual
high infectious doses of MVA (MOI 100). Remarkably, the
overall amount of Her-2/neu being detectable by FACS on
infected DC seemed comparable to levels measured on human
LCL which can promote late viral gene expression.Fig. 3. Cell surface expression of Her-2/neu in human DC. iDC (upper panel) or mD
Cells were then recovered and analyzed by flow cytometry. The histograms display t
line represents the isotype control.Human-monocyte-derived DC do not facilitate intermediate
and late viral gene expression upon MVA infection
Next, we determined whether the lack of MVA late protein
synthesis in monocyte-derived DC is associated with a failure of
viral late mRNA synthesis. For this purpose, we used a recently
established VV-specific RNase protection assay (RPA) as a
highly sensitive method to simultaneously monitor transcription
of all three classes of VV transcripts (Ludwig et al., 2005). The
assay includes three different RNA probes targeting viral early
(ORF 005R), intermediate (ORF 078R) and late (ORF 047R)
MVA transcripts and one probe to assess cellular transcription
(GAPDH). Despite being unable to productively replicate in
HeLa cells, MVA can amplify its genomic DNA and accomplish
synthesis of early, intermediate and late viral gene products
(Drexler et al., 1998; Ludwig et al., 2005; Sutter and Moss,
1992). Thus, the analysis of RNA isolated from MVA-infected
HeLa cells revealed the typical cascade-like pattern of vaccinia
virus transcription (Fig. 4A). First, early gene transcription was
detected at about 1 h post-infection followed by intermediate
gene transcription with highest level at 4 h after infection.
Finally, abundant late gene transcription was prominent at later
times of infection when expression levels of viral early and
intermediate genes had ceased again, coinciding with the shut-
down of cellular transcription. After MVA infection of both iDC
and mDC, however, we found unusual patterns of viral
transcripts (Fig. 4B). To our surprise, high level of viral early
gene expression appeared to continue until at least 12 h post-
infection together with intermediate and late gene transcripts
being detectable from 5 h and 10 h post-infection on,C (lower panel) were infected at different MOI with MVA-Her-2/neu for 12 h.
he number of cells counted with various intensities of fluorescence. The broken
Fig. 4. Analysis of viral transcription in human DC. RNase protection assays
were performed on total RNA isolated from MVA-Her-2/neu-infected DC (MOI
20) at indicated times post-infection (h p.i.) using biotinylated probes (P)
designed to monitor typical viral early (Early), intermediate (Inter) and late
(Late) mRNAs as well as cellular GAPDH message (Cellular). Bands that shift
to the expected size (framed bands) are representative for the corresponding
transcripts. Left-over bands are due to incomplete RNase digest of GAPDH and
ORF 005R probe. P indicates full-length probes, U samples from uninfected
controls. (A) In MVA-infected HeLa cells, early, intermediate and late viral
transcripts are synthesized in a cascade-like pattern. Cessation of cellular
transcription is indicated by the disappearance of protected cellular probes at 7.5
h post-infection. (B) Ongoing viral early transcription in iDC and mDC with
delayed detection of intermediate and late viral RNA. The weak signal of the
uninfected control in the cellular box was confirmed by RT-PCR (not shown).
(C) Analysis of RNA from sorted and infected mDC (CD83+, CD19−) reveals
early viral gene expression only.
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transcription occurred in both types of infected DC. As active
transcription of viral early and late genes is unlikely to
simultaneously take place in an infected cell, we consideredheterogeneous cell populations in DC preparations being
responsible for the detection of apparently mixed transcription
patterns. We suspected a possible contamination of DC
preparations with, e.g. B cells, because this cell type is also
contained in human PBMC and is already known to allow for
MVA late gene expression (Drexler et al., 1998). Indeed, FACS
analysis showed about 5–10% B cells (gated on CD19) being
present in all DC preparations used in this study (data not
shown). Indeed, FACS analysis showed about 5–10% B cells
being present in all DC preparations used in this study (data not
shown). To clearly reveal the transcriptional phenotype of MVA
infection in DC, we depleted B cells by sorting mDC for CD83-
positive and CD19-negative cells using a MoFlo cytometer. As
shown in Fig. 4C, the infection of sorted DC populations (>95%
CD83-positive cells) resulted in high level synthesis of early
viral RNAwhereas intermediate or late viral gene products were
not detected. Thus, our data clearly demonstrate that MVA gene
expression in DC is exclusively restricted to transcription of
viral early genes.
Viability of DC following MVA-Her-2/neu infection
Since cell viability may be a critical factor, e.g. for the
efficacy of immunotherapeutic approaches based on adoptive
transfer of virus-infected cells, we wished to analyze the onset
of cell death upon MVA infection of iDC or mDC. We
monitored for signs of apoptosis or necrosis in cells that had
been differentially stained with PI (necrotic cells) and with
Annexin V (apoptotic cells) at 12, 24, 36, 48 or 60 h post-
infection with MVA-Her-2/neu (Koopman et al., 1994; Vermes
et al., 1995). These cells were analyzed by FACS using
different gating strategies based on cell morphology deter-
mined by forward (FS) and sideward scatter (SS) intensity
(Figs. 5A–C). In general, we found two major distinct
populations within infected DC preparations, either (i) living
cells being negative for PI and Annexin V or (ii) apoptotic/
necrotic dead cells positively stained for PI and Annexin (Fig.
5A). Interestingly, these two populations strictly correlated to
morphological parameters based on cellular size and granu-
larity. Analysis of large iDC or mDC only detected cells
remaining negative upon staining with PI and Annexin V and
therefore identified the living cell population (Fig. 5B). The
gating on morphologically smaller cells determined the
population of necrotic or apoptotic cells which positively
stained with PI and Annexin V (Fig. 5C). Fig. 5 shows the
analysis of MVA and mock-infected iDC and mDC 36 h post-
infection and is representative for the kinetic analysis,
summarized in Table 1. Briefly, at 36 h after infection with
MVA-Her-2/neu MOI 10, we found more than 30% of iDC
and about 75% of the mDC population alive. However, 60
h post-infection, we detected only 8% viable iDC, while living
mDC still accounted for more than 50% of the total cell
population. These data suggest that mDC compared to iDC
could tolerate MVA infection for a longer time period.
Nonetheless, more than half of both DC populations (iDC
60%, mDC 83%) remained alive for at least 24 h using a dose
of recombinant MVA infecting more than 90% of all cells.
Fig. 5. MVA-Her-2/neu-infected iDC are more susceptible to apoptosis than mDC. Panels A–C show a representative FACS analysis of infected DC using three
different gating strategies based on cell morphology determined by forward (FS) and sideward scatter (SS) intensity at 36 h after infection. To obtain comparable levels
of infection, MVA-Her-2/neu was added to mDC at an MOI of 10 and to iDC at an MOI of 5. Viability was monitored by staining dead cells using PI and Annexin V.
(A) The gating comprises of all cells of various sizes contained in the DC preparations including viable and apoptotic DC. (B) Viable DC. (C) Double positive,
apoptotic/necrotic DC.
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Table 1
Apoptosis in MVA-Her-2/neu-infected DC MOI 10 (% poptotic cells, Annexin
V positive)
h p.i. 12 h 24 h 36 h 48 h 60 h
mDC mock 15 12 4 5 10
mDC MVA 11 17 25 39 44
iDC mock 10 10 12 10 11
iDC MVA 19 40 68 85 92
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and presentation of heterologous antigens.
MVA-Her-2/neu infection of iDC leads to an inhibition of
maturation
The induction of apoptosis in DC by MVA infection in
combination with the profound shut-off of host mRNA (Fig. 4) and
protein synthesis (Fig. 3) leads to the question if an infected iDC is
still able to mature. To answer that question, we compared the
maturation capacity of infected iDC (MOI 5) with uninfected iDC.
Fig. 6 shows that infected, viable iDC are still able to upregulate
CD80, CD83 and CD86 24 h after treatment with maturation
inducing cytokines compared to uninfected non-cytokine-treated
iDC. However, the upregulation of these molecules is markedly
reduced compared to uninfected and cytokine-treated iDC. CD71,
the transferrin receptor, was used as a non-immunological control
marker. Since the functionality of DC as professional antigen-
presenting cells is believed to be highly dependent on expression of
maturation markers such as costimulatory molecules CD80 and
CD86, and MHC class II molecules, the impaired maturation of
infected iDC could be interpreted as a DC-specific immune evasion
mechanism.However, it seemsmore likely to reflect a consequence
of the general host protein shut-off typically found in VV-infected
cells.
MVA-Her-2/neu infection of mDC allows for unimpaired
surface expression of costimulatory molecules and other
maturation markers
Next, we wished to investigate the influence of MVA infection
on the maturation status of mDC by determining the expression of
these molecules on the surface of infected cells. Mature DC can be
distinguished from iDC by high expression levels of MHC class II,Fig. 6. MVA-Her-2/neu infection inhibits the maturation of immature DC. iDC have be
maturation inducing cytokines for 24 h (bold line), or MVA-Her-2/neu-infected (MOcostimulatory molecules and the DC-restricted marker CD83.
These surface proteins are essential for mature DC to develop their
full capacity as professional antigen-presenting cells. To investigate
the expression level of maturation markers in infected DC, we
performed a double staining for Her-2/neu and the respective
marker molecules to ensure the analysis of exclusively infected
cells. To scrutinize changes in kinetics and levels of marker
expression after MVA-Her-2/neu infection, mDC were infected at
MOI 5, 10 and 100 and then analyzed by FACS at 12, 36 or 60
h after infection. Fig. 7 shows a representative analysis at MOI 10.
We simultaneously used the two different gating strategies for
discrimination of alive or dead MVA-Her-2/neu-infected cells
based on i)morphological discrimination in the FS/SS diagram (see
also Fig. 5) as well as ii) analysis of Her-2/neu in the corresponding
histogram (Fig. 7A).DCpopulationswere compared for expression
of the activation markers CD80, CD86, CD83, HLA-DR and as
control marker the transferrin receptor CD71 (Fig. 7B). Impor-
tantly, in living cells, we detected a slight reduction of CD86 on
MVA-infected DC as compared to mock-infected DC early in
infection, while at later times CD86 was found to be expressed at
comparable levels on both populations. In contrast, however we
observed a gradual reduction of CD86 in apoptotic Her-2/neu-
positive DC that became particularly prominent at 60 h after
infection. CD83- and HLA-DR expression in MVA-infected and
mock-infected DC remained comparable at all times analyzed. In
contrast, CD80 was expressed at slightly lower levels on MVA-
infected cells compared to mock-infected mDC. CD71 expression
seemed even slightly upregulated in infected DC which might be
due to a cellular activation mediated by MVA infection.
Generally, apart from CD83, the surface expression of all
maturation markers tested was reduced in the apoptotic/necrotic
DC population, with some variation depending on the time of
analysis. Importantly, however, monitoring exclusively living
and MVA-Her-2/neu-infected mDC, we detected no down-
regulation of costimulatory molecules or other maturation
markers.
MVA-vector-infected iDC and mDC are specifically lysed by a
human CTL line
Next, we tested MVA-vector-infected iDC or mDC for their
capacity to endogenously process and present peptides from
recombinant antigen in anMHC-class-I-restricted manner. Afteren mock-infected and left untreated (dotted line), mock-infected and treated with
I 5) and treated with cytokines for 24 h (shaded).
Fig. 7. MVA-Her-2/neu-infected mDC express Her-2/neu and maturation markers at high levels. (A) Depiction of the gating strategy to analyze live or dead DC
expressing Her-2/neu after infection. (B) Staining of cell surface markers onMVA-Her-2/neu-infected mDC at 12, 36 or 60 h post-infection (with MOI 10). Viable cells
from the upper gate are represented by filled histograms. Apoptotic cells from the lower gate correspond to light lines. Mock-infected DC are shown by dotted lines.
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Fig. 8. Recognition of MVA-hTyr-infected DC by the tyrosinase 369–377
peptide-specific human CD8+ CTL line BST5. Specific 51Cr release is shown at
the indicated E:T ratios. iDC (circles) or mDC (squares) were either infected
with MVA-hTyr (closed symbols) or mock-infected (open symbols).
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tyrosinase (MVA-hTyr) (Drexler et al., 1999), iDC and mDC
were specifically lysed by the human CD8+ T-cell line BST5
recognizing the human tyrosinase peptide 369–377 presented
by HLA-A*0201 (Fleischer et al., 2004) (Fig. 8). Comparing
the lytic activities at various effector to target ratios, we found
very similar CTL-mediated recognition of MVA-hTyr-infected
iDC and mDC. These data clearly suggested that MVA-vector-
infected mature and immature human DC can effectively
translate, process and present MVA produced proteins to
activate antigen-specific CTL.
Discussion
Previous work characterizing infection of human DC with
replication-competent conventional VV had suggested viral
interference with DC function (Drillien et al., 2000; Engelmayer
et al., 1999; Jenne et al., 2000). Suspecting a particular benefit
of antigen delivery by replication-deficient vaccinia virus MVA,
we extended these investigations and analyzed monocyte-
derived immature and mature DC after MVA infection. Recent
clinical evaluations suggest the transfer of antigen-loaded
autologous monocyte or CD34+ progenitor-cell-derived DC
as a promising approach to elicit a specific immune response
against HIV or human melanoma (Di Nicola et al., 2004; Lu et
al., 2004). In particular, the success of a protocol using CD34+
cell-derived DC infected with recombinant MVA expressing
human tyrosinase as a tumor antigen had spurred our interest to
study the interactions of DC and MVAvectors in more detail. In
this study, we determined the effect of MVA infection on the
viability, maturation and antigen presentation capacity of
human DC. We clearly demonstrate that MVA gene expression
in both mature and immature monocyte-derived DC was
restricted to viral early gene transcription. This finding is
supported by other work reporting the relevance of early gene
expression when using replication-competent VV or avipox-
virus vectors for infection of human macrophages and human or
murine DC (Broder et al., 1994; Bronte et al., 1997; Brown etal., 1999; Subklewe et al., 1999). In fact, this restriction has a
major consequence in our understanding of the induction of an
immune response against MVA or the delivered recombinant
antigen since direct presentation of late gene products seems
impossible in infected DC. Indeed, using a highly sensitive
detection system based on RNase protection, we also revealed
minor amounts of viral late transcripts in MVA-infected DC
populations. Yet, our experiments suggested that this late gene
expression is due to infected B cells usually being present at low
numbers in human DC preparations (Drexler et al., 1998).
Nevertheless, we cannot formally rule out the possibility that
subset(s) of human DC due to a different development stage or
distinct origin are permissive for viral late gene expression as
reported for MVA infection of unpurified CD34+ progenitor
produced DC (Di Nicola et al., 1998). In general, MVA
infection of DC was more efficient with iDC preparations
requiring less MOI for maximum infection as compared to
mDC. This finding might be attributed to the high phagocytic
activity typically found in iDC (Banchereau and Steinman,
1998; Caux et al., 1997) which possibly supports MVA entry as
suggested for infections with conventional VV (Drillien et al.,
2000). Despite the restriction to early viral gene expression,
infection of both mDC and iDC resulted in production of
surprisingly high amounts of recombinant Her-2/neu. In this
respect, the lower viral early promoter activity might be
compensated by a prolonged maintenance of early transcription
of the target gene in MVA-infected DC. In fact, when focusing
our analysis on living cells, we detected cells strongly
expressing Her-2/neu even at 60 h after MVA-Her-2/neu
infection. Infected mDC maintained the costimulatory mole-
cules CD80, CD86 as well as the maturation marker CD83 at
high levels. We did not observe a significant down- or
upregulation of cell surface markers in infected living cells.
However, we found a slight reduction of CD80 expression
which is in line with recent findings characterizing conventional
VV infections in DC (Drillien et al., 2000; Nagorsen et al.,
2003; Prabakaran et al., 2002). Data from other experiments
demonstrating severe changes of surface marker expression in
VV-infected DC and differing from our results may be
explained by the use of the more cytopathogenic VV strain
Western Reserve, possibly resulting in high levels of cell death
among infected cells (Engelmayer et al., 1999; Jenne et al.,
2000; Nagorsen et al., 2003). This might be of particular
relevance since in these studies apoptotic cells have not been
unambiguously excluded from analysis. Interestingly, Drillien
et al. reported a moderate maturation of MVA-infected human
DC without further maturation stimulus and independently of
viral gene expression as shown by UV inactivation (Drillien et
al., 2004). We extended that finding by additionally treating
MVA-infected DC with maturating cytokines. Our data revealed
that MVA-infected iDC do not fully mature compared to mock-
infected iDC, despite initial upregulation of CD80, CD83 and
CD86. A comparable, impaired maturation of iDC upon
infection with replication-competent VV has been interpreted
as a specific mechanism of immune evasion (Engelmayer et al.,
1999; Jenne et al., 2000; Nagorsen et al., 2003). However, in the
light of the severe shut-down of cellular protein biosynthesis
285W. Kastenmuller et al. / Virology 350 (2006) 276–288(Figs. 2 and 3), which is a general consequence of VV infection
in various cell types (Moss and Salzman, 1968; Esteban and
Metz, 1973), we interpret this finding to apply to all newly
synthesized proteins, regardless of their immunological
relevance.
We have shown that human iDC and mDC infected with
recombinant MVA can serve as functional antigen-presenting
cells to stimulate target antigen-specific and MHC-class I-
restricted T-cell responses in vitro (Fig. 8) (Di Nicola et al.,
1998; Drexler et al., 1999). For replication-competent VV, a
number of other studies confirm similar functional activity of
infected DC in various in vitro and in vivo models (Bonini et
al., 2001; Norbury et al., 2002; Prabakaran et al., 2002; Yang
et al., 2000; Yee et al., 1996). However, we still have very
limited knowledge whether vector virus-infected DC act
directly as the key inducers of a target antigen-specific cellular
immune response after in vivo DC transfer to patients. At least
with regard to antigens driven by late viral promoters, direct
presentation by dendritic cells is very unlikely to occur (Fig.
4C). In vivo, T cells can also be primed by means of antigen
cross-presentation (Cresswell, 2004; Norbury et al., 2004;
Shen et al., 2002), and DC are known for their particular
capacity to cross-present viral antigens and apoptotic cells
(Ackerman et al., 2003; Houde et al., 2003; Larsson et al.,
2004; Sigal et al., 1999). Therefore, it is likely that both direct
priming and cross-priming contribute to the induction of
antigen-specific CD8+ CTL in vivo. MVA-infected DC can be
specifically recognized by T cells (Fig. 8) in vitro. Whether
this interaction leads to direct priming in vivo still remains
unclear. Detailed in vivo studies will be required to finally
understand the specific advantage of transferred MVA-infected
DC compared to MVA alone. One interesting aspect will be
the evaluation and comparison of vector and target antigen-
specific immune responses under both conditions. In that
respect, MVA-infected DC might have a specific phenotype of
anti-vector immunity due to restricted viral gene expression
which could possibly lead to reduced vector-specific immune
responses. Thereby, infected DC might have a specific benefit
and advantage in prime boost regimen. Yet, our in vitro data
might help to explain the successful use of adoptively
transferred MVA-infected human DC in several aspects.
First, MVA-infected iDC and mDC produce substantial
amount of recombinant protein despite restricted viral gene
expression. Second, induction of apoptosis upon MVA
infection is varying between iDC and mDC, with the latter
being more resistant. Third, viable MVA-infected mDC do not
downregulate costimulatory molecules in contrast to reports on
replication-competent VV. Finally, although MVA-infected
iDC do not fully mature under established maturation stimuli,
they can process and present peptides derived from the
recombinant antigen to a comparable level as mDC. In this
study, we show that viability and maturation status are
differentially influenced in MVA-infected human iDC and
mDC. We also demonstrate previously unknown aspects of
MVA and DC interaction with regard to viral transcription and
in comparison reveal new differences concerning phenotypic
changes reported on replication competent VV.Materials and methods
Viruses
Vaccinia virus (VV) strain MVA was originally obtained from
Anton Mayr (University of Munich, Germany). MVA from the
582nd (cloned isolate F6) passage on CEFwere used for this study.
Recombinant MVA expressing the human her-2/neu gene and the
human tyrosinase gene, respectively, under control of the VV-
specific natural early/late promoter P7.5 (MVA-Her-2/neu) were
constructed as described previously (Staib et al., 2000; Staib et al.,
2004). DNA genomes of recombinant viruses were analyzed by
Southern blot hybridization and PCR. All viruses were propagated
and titrated following standard methodology.
Protein analysis
Protein lysates from infected human HeLa cells were
resolved by electrophoresis on a SDS–6% polyacrylamide gel
and electroblotted onto nitrocellulose at 15 V for 1 h in a buffer
containing 25 mM Tris, 192 mM glycine, 0.05% SDS and 20%
methanol. Blots were blocked overnight at 4°C in a phosphate-
buffered saline blocking buffer containing 1% bovine serum
albumin (BB) and incubated for 2 h at RT with Her-2/neu-
specific c-neu-antibody (9G6) (Oncogene) diluted in BB at a
final concentration of 2.5 μg/ml. After washing and incubation
for 1 h at RT with 125I-labeled sheep anti-mouse IgG
(Amersham), these are diluted 500-fold in BB, washed again
and exposed to a phosphor imaging plate (Type BAS-IIIs, Fuji)
for evaluation with a phosphor imaging analyzer (Personal
Molecular Imager FX, Bio-Rad). For analysis of [S35]
methionine-labeled polypeptides, cells were infected and
labeled as previously described (Sutter and Moss, 1992).
Cytoplasmatic extracts were prepared, and samples were
analyzed by SDS-PAGE.
Cell lines
SK-MEL-28 (ATCCHTB 72) is a human melanoma cell line.
EBV-transformed B-LCL were established by culturing periph-
eral blood mononuclear cells (PBMC) with supernatant from
B95.8 cells in the presence of 1 μg/ml of cyclosporin A. Cells
were cultured in RPMI 1640 or DMEM supplemented with 10%
FCS and 100 U/ml penicillin and 100 μg/ml streptomycin.
CTL line
The human HLA-A*0201-restricted CD8+ CTL line BST5
specific for the human tyrosinase peptide 369–377 was
maintained as described (Fleischer et al., 2004). Briefly,
responding T cells were restimulated weekly with peptide-
pulsed DC in the presence of rIL-2 and rIL-7.
Chromium release assay
The cytolytic activity was analyzed as described previously
(Drexler et al., 1999). Briefly, DC were infected with MVA at an
286 W. Kastenmuller et al. / Virology 350 (2006) 276–288MOI of 10, washed once, labeled for 1 h at 37 °C with 100 μCi
Na51 CrO4 and then washed four times. Labeled target cells
were then cocultivated with effector cells at different E:T ratios
for 4 h. Thereafter, supernatants were collected and specific
51Cr release was determined.
DC isolation, culture and infection
Immature DC (iDC) from different healthy donors were
generated by culturing adherent monocytes with GM-CSF
and IL-4 for 7 days (purity 70–90%, analyzed by FACS) and
were matured into CD83+ mDC in the presence of cytokines
(TNFα, IL-1β, IL-6 and PGE2) as previously described
(Fleischer et al., 2004; Jonuleit et al., 1997). Cells to be
infected were counted and washed in RPMI, as described
(Drexler et al., 1999; Staib et al., 2000). Briefly, for
infection, purified virus was added to the cells at an MOI
(multiplicity of infection) ranging from 1 to 100 for 2 h.
After infection, cells were washed three times and further
cultivated.
Ribonuclease protection assay (RPA)
HeLa cells and DC were mock-infected or infected with
MVA at MOI 20 and incubated at 4 °C for 30 min to allow virus
adsorption and synchronization of infection. Subsequently, cells
were washed and further incubated at 37 °C. Total RNA was
isolated at varying periods post-infection with TRIzol reagent
(Invitrogen) following the manufacturer's instructions. For
RPA, 5 μg total RNA per reaction was applied as described
previously (Ludwig et al., 2005). Briefly, biotinylated anti-sense
riboprobes specific for MVA ORF 005R, 078R and 047R
transcripts and human GAPDH were included. Electrophoretic
separation of RPA samples occurred in pre-cast 6% polyacryl-
amide urea gels, and RNA was transferred onto positively
charged nylon membrane via semi-dry blotting. For detection,
North2South Chemiluminescent Hybridization and Detection
Kit (PIERCE) was used.
Flow cytometric analysis and antibodies
Cells were harvested, washed and resuspended in PBS
containing 0.5% BSA. After Fcγ receptor blocking (Milteny-
Biotec) for 30 min at 4°C, phenotypic analyses were
performed by flow cytometric using saturating concentrations
of the following PE-conjugated antibodies: CD71 (M-A712)
and CD83 (HB15A) (Immunotech), CD80 (BB1), CD86
(IT2.2) and HLA-DR (TÜ 36); HLA-DR (G46-6) FITC-
conjugated (all PharMingen). Conjugated isotype-matched
mAbs were used as controls. Her-2/neu-specific staining was
performed using mAb c-neu (Ab-2) (9G6) and FITC-
conjugated F(ab′)2 goat anti-mouse Ig (Zymed). Apoptosis
and necrosis were assessed by staining with FITC-Annexin
and propidium iodide (PI) using Annexin V Kit (Immuno-
tech), according to the manufacturer's instructions. Fluores-
cence analyses were performed with EPICS Elite ESP flow
cytometer (Coulter Electronics).Acknowledgments
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